[Efficacy studies]

Abstract

Pravafenix(®) is a fixed-dose combination of 40mg of pravastatin and 160 mg of fenofibrate. The rationale behind the use of Pravafenix(®) is based on the increased residual cardiovascular risk observed in high risk patients with hypertriglyceridemia and/or low HDL cholesterol levels despite treatment with statins in monotherapy. In this article, we review the available evidence on the clinical efficacy of Pravafenix(®), which shows complementary benefits in the overall lipid profile of high risk patients with mixed dyslipidemia not controlled with 40-mg pravastatin or 20-mg simvastatin.

Keywords: Atherogenic dyslipidemia; Clinical efficacy; Colesterol no HDL; Dislipemia aterogénica; Eficacia clínica; Non-HDL cholesterol; Pravafenix(®); Residual cardiovascular risk; Riesgo cardiovascular residual.